Enhancing exposure-based therapy from a translational research perspective.
Combining an effective psychological treatment with conventional anxiolytic medication is typically not more effective than unimodal therapy for treating anxiety disorders. However, recent advances in the neuroscience of fear reduction have led to novel approaches for combining psychological therapy and pharmacological agents. Exposure-based treatments in humans partly rely on extinction to reduce the fear response in anxiety disorders. Animal studies have shown that D-cycloserine (DCS), a partial agonist at the glycine recognition site of the glutamatergic N-methyl-D-aspartate receptor facilitates extinction learning. Similarly, recent human trials have shown that DCS enhances fear reduction during exposure therapy of some anxiety disorders. This article discusses the biological and psychological mechanisms of extinction learning and the therapeutic value of DCS as an augmentation strategy for exposure therapy. Areas of future research will be identified.
Department of Psychology, Boston University, 648 Beacon Street, 6th Floor, Boston, MA 02215-2002, USA. shofmann@bu.edu
Stefan G
SG
Hofmann
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000628:therapy*; D003131:Combined Modality Therapy; D003523:Cycloserine / Q000627:therapeutic use*; D003887:Desensitization, Psychologic; D005108:Extinction, Psychological; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000628:therapy; D016584:Panic Disorder / Q000628:therapy; D010698:Phobic Disorders / Q000628:therapy
D014151:Anti-Anxiety Agents; D003523:Cycloserine